Drugmaker Scynexis said on Monday it would voluntarily recall its antifungal drug Brexafemme from the market and put a temporary hold on studies of the therapy due to the potential risk of cross contamination with another compound.
Tag Archive for: brexafemme
This exclusive licence agreement gives GSK rights to commercialize Brexafemme for vulvovaginal candidiasis and recurrent VVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.